BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

A number of hedge funds and other institutional investors have recently bought and sold shares of BCLI. BlackRock Inc. raised its holdings in shares of Brainstorm Cell Therapeutics by 132.0% in the first quarter. BlackRock Inc. now owns 384,000 shares of the biotechnology company's stock valued at $1,782,000 after buying an additional 218,461 shares during the last quarter. EAM Investors LLC acquired a new position in Brainstorm Cell Therapeutics in the 1st quarter valued at about $603,000. Phoenix Holdings Ltd. increased its position in Brainstorm Cell Therapeutics by 307.7% in the 1st quarter. Phoenix Holdings Ltd. now owns 118,533 shares of the biotechnology company's stock valued at $534,000 after acquiring an additional 89,456 shares during the period. Raymond James & Associates raised its stake in Brainstorm Cell Therapeutics by 65.3% during the 1st quarter. Raymond James & Associates now owns 200,950 shares of the biotechnology company's stock valued at $932,000 after acquiring an additional 79,350 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Brainstorm Cell Therapeutics by 3,523.5% during the 1st quarter. JPMorgan Chase & Co. now owns 72,977 shares of the biotechnology company's stock worth $339,000 after acquiring an additional 70,963 shares during the period. Institutional investors own 12.62% of the company's stock.

https://www.marketbeat.com/instant-alerts/nasdaq-bcli-a-buy-or-sell-right-now/